Reconnecting

The current page stays visible while onset.to reconnects in the background.

Psilocybin therapy could become an FDA-approved treatment for treatment-resistant depression in the United States

Open original

Psilocybin therapy could become an FDA-approved option for treatment-resistant depression, following two positive Phase 3 trials of Compass Pathways' COMP360. A 2026 study found lower depression scores with COMP360 than with placebo, while earlier research suggested benefits may last a year alongside supportive psychotherapy. Researchers propose changes in brain plasticity and the default mode network as possible mechanisms, but note that psychedelic effects make trials difficult to blind. Experts anticipate supervised clinical administration rather than take-home prescriptions. Risks include anxiety, elevated blood pressure and possible psychosis in vulnerable people, making medical and psychiatric screening important. Approval remains uncertain, and psilocybin is federally classified as a Schedule I substance.